[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:chronic-lymphocytic-leukemia:17p":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Chronic Lymphocytic Leukemia","17p",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05254743","A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)\u002FSmall Lymphocytic Lymphoma (SLL)",[12],"Phase 3","RECRUITING","2026-08-26T02:15:34.659160Z","2026-05-05T02:43:26.921381Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT03128879","Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL",[20],"Phase 2","2026-08-03T03:15:35.967581Z","2026-04-29T02:57:57.177996Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT04959175","Phase I\u002FII Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies",[27],"Phase 1\u002FPhase 2","2026-08-26T02:15:23.202838Z","2026-05-05T02:43:28.644953Z"]